KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Change in Receivables (2019 - 2025)

GoodRx Holdings' Change in Receivables history spans 7 years, with the latest figure at $30.2 million for Q4 2025.

  • For Q4 2025, Change in Receivables rose 99.67% year-over-year to $30.2 million; the TTM value through Dec 2025 reached $88.0 million, up 3684.01%, while the annual FY2025 figure was $88.0 million, 3684.01% up from the prior year.
  • Change in Receivables for Q4 2025 was $30.2 million at GoodRx Holdings, up from $14.7 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $30.2 million in Q4 2025 and bottomed at -$31.0 million in Q3 2024.
  • The 5-year median for Change in Receivables is $6.9 million (2023), against an average of $7.2 million.
  • The largest annual shift saw Change in Receivables skyrocketed 4084.36% in 2021 before it crashed 1287.59% in 2024.
  • A 5-year view of Change in Receivables shows it stood at $19.6 million in 2021, then plummeted by 119.14% to -$3.7 million in 2022, then surged by 40.4% to -$2.2 million in 2023, then surged by 777.91% to $15.1 million in 2024, then soared by 99.67% to $30.2 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Change in Receivables are $30.2 million (Q4 2025), $14.7 million (Q3 2025), and $28.9 million (Q2 2025).